320 related articles for article (PubMed ID: 29542120)
1. The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol.
Geng Y; Lai Q; Xun Y; Jin L
Int J Gynaecol Obstet; 2018 Jul; 142(1):97-103. PubMed ID: 29542120
[TBL] [Abstract][Full Text] [Related]
2. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
3. A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol.
Li Y; Duan Y; Yuan X; Cai B; Xu Y; Yuan Y
Front Endocrinol (Lausanne); 2021; 12():688654. PubMed ID: 34594300
[TBL] [Abstract][Full Text] [Related]
4. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
[TBL] [Abstract][Full Text] [Related]
5. A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study.
Zhang Y; Xu Y; Yu J; Wang X; Xue Q; Shang J; Yang X; Shan X
J Ovarian Res; 2023 Jun; 16(1):119. PubMed ID: 37370146
[TBL] [Abstract][Full Text] [Related]
6. Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of
Zhang C; Wu F; Wu Z; Sun B; Chen C; Qian W
Front Endocrinol (Lausanne); 2021; 12():739773. PubMed ID: 34707571
[TBL] [Abstract][Full Text] [Related]
7. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
8. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
Oehninger S; Nelson SM; Verweij P; Stegmann BJ
Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
11. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
Huang P; Tang M; Qin A
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
[TBL] [Abstract][Full Text] [Related]
12. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
13. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
[TBL] [Abstract][Full Text] [Related]
14. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
16. The effect of a transient premature luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin-releasing hormone antagonist flexible protocol.
Zhang D; Zhang D; Sun Z; Deng C; Yu Q; Zhen J
Gynecol Endocrinol; 2020 Jun; 36(6):550-553. PubMed ID: 31829082
[TBL] [Abstract][Full Text] [Related]
17. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
Younis JS; Izhaki I; Ben-Ami M
Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
Wang Y; Kuang Y; Chen Q; Cai R
Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
[TBL] [Abstract][Full Text] [Related]
20. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
